滤泡状甲状腺癌肺转移灶对碘-131治疗反应显著而残留甲状腺组织持续显影
一例66岁男性滤泡状甲状腺癌全切除术后患者,未服左甲状腺素却出现严重甲状腺毒症。碘-131全身显像及SPECT/CT发现多发摄碘肺转移灶(最大径1.4 cm)及残留甲状腺,诊断为功能性肺转移灶所致甲状腺毒症。给予7.4 GBq碘-131治疗后6个月,肺转移灶显著缩小、甲状腺球蛋白下降,但残留甲状腺仍显影。
要点
- 功能性肺转移灶可致甲状腺毒症,甲状腺切除术后未服左甲状腺素者需警惕。
- 碘-131治疗6个月后肺转移灶显著缩小且甲状腺球蛋白下降。
- 残留甲状腺组织在碘-131治疗后6个月仍持续显影。
核心结论
- 滤泡状甲状腺癌的功能性肺转移灶可导致甲状腺毒症,碘-131治疗后肺转移灶反应显著而残留甲状腺持续显影。
研究设计与样本
- 单例病例报告:66岁男性滤泡状甲状腺癌全切除术后患者。
主要发现
- 碘给药前甲状腺功能检查显示严重甲状腺毒症,患者甲状腺切除术后未服左甲状腺素。
- 185 MBq碘-131全身显像及SPECT/CT显示多发摄碘肺转移灶,最大肿瘤直径1.4 cm,并见残留甲状腺。
- 给予7.4 GBq碘-131治疗6个月后,肺转移病变显著减少且甲状腺球蛋白水平下降,但残留甲状腺仍显影。
关键数值与推荐
- 碘-131治疗剂量为7.4 GBq;诊断性显像剂量为185 MBq。
- 肺转移灶最大肿瘤直径为1.4 cm。
临床怎么用
- 甲状腺癌术后未服左甲状腺素而出现甲状腺毒症时,应警惕功能性转移灶可能,可行碘-131显像评估。
- 对摄碘性肺转移灶可考虑碘-131治疗,但需注意残留甲状腺可能持续显影。
局限性
- 单例病例报告,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 66-year-old man with follicular thyroid cancer after total thyroidectomy was referred for I therapy. Thyroid function tests before I administration exhibited severe thyrotoxicosis although the patient did not take levothyroxine after thyroidectomy. A 185 MBq I whole-body scintigraphy and SPECT/CT revealed multiple iodine-avid pulmonary metastases with the largest tumor diameter of 1.4 cm and remnant thyroid. A diagnosis of thyrotoxicosis caused by hyperfunctioning pulmonary metastases was then made. The patient was administered 7.4 GBq of I. Six months after I therapy, a significant reduction of the pulmonary metastatic disease and thyroglobulin level was observed. However, the remnant thyroid was still visualized.
引用
- Tian T, Chen Y, Xiang Y, et al. Remarkable Response of Pulmonary Metastases Rather Than Remnant Thyroid in 131I Therapy of Follicular Thyroid Cancer. Clin Nucl Med. 2019. PMID: 30688748. doi:10.1097/RLU.0000000000002477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。